

Oncology Today with Dr Neil Love: Management of Localized Non-Small Cell Lung Cancer with EGFR Tumor Mutations (Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following outcomes was reported from the Phase III ADAURA trial evaluating osimertinib as adjuvant therapy for Stage IB to IIIA NSCLC with EGFR mutations?**
 - a. Significant benefit versus placebo in patients with Stage IB to IIIA NSCLC**
 - Significant benefit versus placebo only in patients with Stage II and IIIA NSCLC, but not in patients with Stage IB disease
 - No benefit in any subset versus placebo
- 2. Which of the following is true regarding disease recurrence in the brain for patients receiving adjuvant osimertinib in the Phase III ADAURA trial?**
 - Higher incidence when compared to placebo arm
 - b. Lower incidence when compared to placebo arm**
 - Similar incidence as the placebo arm
- 3. Safety analysis in the Phase III ADAURA trial comparing osimertinib to placebo as adjuvant therapy for patients with resected early-stage NSCLC with EGFR mutations showed which of the following outcomes with osimertinib?**
 - High incidence of Grade III/IV toxicities
 - b. Mostly Grade I/II toxicities**
- 4. The Phase III NeoADAURA trial is examining which of the following agent(s) with or without platinum-based chemotherapy versus chemotherapy alone as neoadjuvant therapy for patients with early-stage NSCLC with EGFR mutations?**
 - a. Osimertinib**
 - Osimertinib plus durvalumab